These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 26105382)

  • 21. Association between the high soluble fms-like tyrosine kinase-1 to placental growth factor ratio and adverse outcomes in asymptomatic women with early-onset fetal growth restriction.
    Shinohara S; Uchida Y; Kasai M; Sunami R
    Hypertens Pregnancy; 2017 Aug; 36(3):269-275. PubMed ID: 28737473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening for fetal growth restriction using ultrasound and the sFLT1/PlGF ratio in nulliparous women: a prospective cohort study.
    Gaccioli F; Sovio U; Cook E; Hund M; Charnock-Jones DS; Smith GCS
    Lancet Child Adolesc Health; 2018 Aug; 2(8):569-581. PubMed ID: 30119716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile.
    Rana S; Schnettler WT; Powe C; Wenger J; Salahuddin S; Cerdeira AS; Verlohren S; Perschel FH; Arany Z; Lim KH; Thadhani R; Karumanchi SA
    Hypertens Pregnancy; 2013 May; 32(2):189-201. PubMed ID: 23725084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia.
    Palomaki GE; Haddow JE; Haddow HR; Salahuddin S; Geahchan C; Cerdeira AS; Verlohren S; Perschel FH; Horowitz G; Thadhani R; Karumanchi SA; Rana S
    Prenat Diagn; 2015 Apr; 35(4):386-93. PubMed ID: 25641027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PP058. The additive effect of plasma levels of sFlt-1/PLGF ratio following the risk classification using both blood pressure levels and uterine artery blood flow impedance in the second trimester on the later occurrence of preeclampsia.
    Ohkuchi A; Hirashima C; Takahashi K; Matsubara S; Suzuki M
    Pregnancy Hypertens; 2012 Jul; 2(3):273. PubMed ID: 26105381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics of hypertensive disorders in twin versus singleton pregnancies.
    Foo JY; Mangos GJ; Brown MA
    Pregnancy Hypertens; 2013 Jan; 3(1):3-9. PubMed ID: 26105734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The association of circulating angiogenic factors and HbA1c with the risk of preeclampsia in women with preexisting diabetes.
    Cohen AL; Wenger JB; James-Todd T; Lamparello BM; Halprin E; Serdy S; Fan S; Horowitz GL; Lim KH; Rana S; Takoudes TC; Wyckoff JA; Thadhani R; Karumanchi SA; Brown FM
    Hypertens Pregnancy; 2014 Feb; 33(1):81-92. PubMed ID: 24354578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. sFlt-1/PlGF ratio as a prognostic marker of adverse outcomes in women with early-onset preeclampsia.
    De Oliveira L; Peraçoli JC; Peraçoli MT; Korkes H; Zampieri G; Moron AF; Sass N
    Pregnancy Hypertens; 2013 Jul; 3(3):191-5. PubMed ID: 26106033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiogenic biomarkers in triage and risk for preeclampsia with severe features.
    Rana S; Salahuddin S; Mueller A; Berg AH; Thadhani RI; Karumanchi SA
    Pregnancy Hypertens; 2018 Jul; 13():100-106. PubMed ID: 30177034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiogenic Factor Estimation as a Warning Sign of Preeclampsia-Related Peripartum Morbidity Among Hospitalized Patients.
    Lopes Perdigao J; Chinthala S; Mueller A; Minhas R; Ramadan H; Nasim R; Naseem H; Young D; Shahul S; Chan SL; Yeo KJ; Rana S
    Hypertension; 2019 Apr; 73(4):868-877. PubMed ID: 30798660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. sFLT1, PlGF, the sFLT1/PlGF Ratio and Their Association with Pre-Eclampsia in Twin Pregnancies-A Review of the Literature.
    Sapantzoglou I; Rouvali A; Koutras A; Chatziioannou MI; Prokopakis I; Fasoulakis Z; Zachariou E; Douligeris A; Mortaki A; Perros P; Ntounis T; Pergialiotis V; Domali E; Athanasiou S; Daskalakis G; Rodolakis A; Panagopoulos P; Pappa KI
    Medicina (Kaunas); 2023 Jun; 59(7):. PubMed ID: 37512044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteinuria in pre-eclampsia: how much matters?
    Chan P; Brown M; Simpson JM; Davis G
    BJOG; 2005 Mar; 112(3):280-5. PubMed ID: 15713140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia.
    Buhimschi CS; Norwitz ER; Funai E; Richman S; Guller S; Lockwood CJ; Buhimschi IA
    Am J Obstet Gynecol; 2005 Mar; 192(3):734-41. PubMed ID: 15746665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PP116. Circulating PlGF can help predict preeclampsia and adverse outcome in patients with suspected preeclampsia or fetal growth restriction.
    Sibiude J; Dionne MD; Guibourdenche J; Le Ray C; Anselem O; Serreau R; Goffinet F; Tsatsaris V
    Pregnancy Hypertens; 2012 Jul; 2(3):302-3. PubMed ID: 26105438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical value of PlGF and the sFlt1/PlGF ratio in the management of hypertensive pregnancy disorders: A retrospective real-world study in China.
    Yang H; Guo F; Guo Q; Wang Y; He P; Zhang H; Wang S
    Clin Chim Acta; 2022 Mar; 528():90-97. PubMed ID: 35104464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maternal clinical disease characteristics and maternal and neonatal outcomes in twin and singleton pregnancies with severe preeclampsia.
    Connolly KA; Factor SH; Getrajdman CS; Bigelow CA; Weintraub AS; Stone JL
    Eur J Obstet Gynecol Reprod Biol; 2016 Jun; 201():36-41. PubMed ID: 27054964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A longitudinal study of plasma levels of soluble fms-like tyrosine kinase 1 (sFlt1), placental growth factor (PlGF), sFlt1: PlGF ratio and vascular endothelial growth factor (VEGF-A) in normal pregnancy.
    Palm M; Basu S; Larsson A; Wernroth L; Åkerud H; Axelsson O
    Acta Obstet Gynecol Scand; 2011 Nov; 90(11):1244-51. PubMed ID: 21568945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary placental growth factor and risk of preeclampsia.
    Levine RJ; Thadhani R; Qian C; Lam C; Lim KH; Yu KF; Blink AL; Sachs BP; Epstein FH; Sibai BM; Sukhatme VP; Karumanchi SA
    JAMA; 2005 Jan; 293(1):77-85. PubMed ID: 15632339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PP054. Predicting preeclampsia at late mid-term pregnancy before occurrence of clinical symptoms: Clinical utility of biomarkers and clinical parameters in a low-risk population.
    Forest JC; Massé J; Bujold E; Lafond J; Charland M; Rousseau F; Giguère Y
    Pregnancy Hypertens; 2012 Jul; 2(3):271. PubMed ID: 26105377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial.
    Duhig KE; Myers J; Seed PT; Sparkes J; Lowe J; Hunter RM; Shennan AH; Chappell LC;
    Lancet; 2019 May; 393(10183):1807-1818. PubMed ID: 30948284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.